Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers Journal Article

   


Authors: Chen, Y.; Chi, P.
Article Title: Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Abstract: Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent "basket" study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing "tumor-agnostic" targeted therapies in rare tumors. © 2018 The Author(s).
Journal Title: Journal of Hematology & Oncology
Volume: 11
ISSN: 1756-8722
Publisher: Biomed Central Ltd  
Date Published: 2018-06-07
Start Page: 78
Language: English
DOI: 10.1186/s13045-018-0622-4
PROVIDER: scopus
PMCID: PMC5992878
PUBMED: 29880008
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048170959&doi=10.1186%2fs13045-018-0622-4&partnerID=40&md5=6104d02e71df7c70a1de9c3041a5af9c
Notes: Article -- Export Date: 2 July 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Yu Chen
    133 Chen
  2. Ping Chi
    172 Chi
Related MSK Work